However, the RPPA data for ccRCC shows expected survival difference based on known general tumor-promoters (such as c-myc, P-cadherin, etc.)and tumor-suppressors (such as PTEN, Tuberin, etc.), arguing for its validity/robustness. This evidence concerns the gene MYC and nonpapillary renal cell carcinoma.